The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Amplification of c‐erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma
Open accessAbstract
BACKGROUND: Overexpression of the epidermal growth factor type II receptor HER‐2/neu has been associated with resistance to chemotherapy and poor survival in several human tumors. In the current study, the authors have determined the frequency and clinical significance of HER‐2/neu gene amplification in uterine serous papillary endometrial carcinoma (USPC), a highly aggressive variant of endometrial carcinoma. METHODS: Fluorescence in situ hybridization (FISH) assay was used to analyze gene amplification in paraffin blocks from 30 women harboring Stage IA–IV USPC treated at the University of Arkansas for Medical Sciences (Little Rock, AR) from 1997 to 2004. Chromosome 17 polysomy status by FISH was also assessed in all specimens. USPC patient survival in relation to HER‐2/neu gene amplification was analyzed using Kaplan–Meier curves in conjunction with the log‐rank test. RESULTS: Amplification of the HER‐2/neu gene by FISH was observed in 14 of the 30 (47%) cases. Heterogeneity was noted in 4 of 14 cases in the amplification of the HER‐2/neu gene within the same tumor samples with pockets of amplified tumor cells amidst nonamplified tumor cells. Patients with USPC harboring tumors with HER‐2/neu gene amplification had a significantly shorter survival time from diagnosis to disease‐related death when compared with FISH‐negative patients (P = 0.0008). African‐American (AA) patients were found to have a poorer prognosis compared with Caucasian (C) women (P = 0.01) and to harbor USPC with significantly higher levels of HER‐2/neu gene amplification (P = 0.02). CONCLUSIONS: HER‐2/neu gene amplification in USPC was found to be an important prognostic indicator for poor outcome that occurs more frequently in AA when compared with C patients. Determination of HER‐2/neu gene amplification may guide clinical management of patients with USPC and may have important implications for the implementation of novel treatment strategies. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Kosary, C. L. (1994) · Seminars in Surgical Oncology · doi:10.1002/ssu.2980100107 · Cited by 417
Cited by
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Classification of endometrial carcinoma: more than two types
Murali, R., Soslow, R. A., & Weigelt, B. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70591-6 · Cited by 647
Boruta, D. M., Gehrig, P. A., Fader, A. N., & Olawaiye, A. B. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.06.011 · Cited by 254
Metadata
- Authors
- Santin, A. D., Bellone, S., Van Stedum, S., Bushen, W., Palmieri, M., Siegel, E. R., De Las Casas, L. E., Roman, J. J., Burnett, A., & Pecorelli, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-09-17
- Volume
- 104
- Issue
- 7
- Pages
- 1391-1397
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2039241242
- Cited by
- 168
- References
- 3
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amplification of c‐erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma. https://app.cochat.ai/papers/10.1002/cncr.21308
- The paper
- Santin, A. D., Bellone, S., Van Stedum, S., Bushen, W., Palmieri, M., Siegel, E. R., De Las Casas, L. E., Roman, J. J., Burnett, A., & Pecorelli, S. (2005). Amplification of c‐erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma. Cancer. https://doi.org/10.1002/cncr.21308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.